Theravance Biopharma Inc (TBPH)

$8.65

-0.15

(-1.7%)▲

Live

Performance

  • $8.63
    $8.78
    $8.65
    downward going graph

    0.23%

    Downside

    Day's Volatility :1.71%

    Upside

    1.48%

    downward going graph
  • $7.44
    $11.71
    $8.65
    downward going graph

    13.99%

    Downside

    52 Weeks Volatility :36.46%

    Upside

    26.13%

    downward going graph

Returns

PeriodTheravance Biopharma IncSector (Health Care)Index (Russel 2000)
3 Months
-14.06%
3.6%
0.0%
6 Months
-6.98%
10.2%
0.0%
1 Year
-3.3%
19.6%
0.0%
3 Years
12.82%
16.8%
-23.0%

Highlights

Market Capitalization
421.7M
Book Value
$3.96
Earnings Per Share (EPS)
-0.95
PEG Ratio
-0.05
Wall Street Target Price
13.2
Profit Margin
-73.61%
Operating Margin TTM
-89.46%
Return On Assets TTM
-6.02%
Return On Equity TTM
-19.27%
Revenue TTM
62.0M
Revenue Per Share TTM
1.25
Quarterly Revenue Growth YOY
3.6999999999999997%
Gross Profit TTM
-12.0M
EBITDA
-39.2M
Diluted Eps TTM
-0.95
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.01
EPS Estimate Next Year
0.06
EPS Estimate Current Quarter
-0.21
EPS Estimate Next Quarter
-0.19

Analyst Recommendation

Buy
    72%Buy
    27%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Theravance Biopharma Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
7
7
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 52.6%

Current $8.65
Target $13.20

Company Financials

FY18Y/Y Change
Revenue
60.4M
↑ 292.37%
Net Income
-215.5M
↓ 24.48%
Net Profit Margin
-357.01%
↑ 1497.96%
FY19Y/Y Change
Revenue
73.4M
↑ 21.61%
Net Income
-236.5M
↑ 9.71%
Net Profit Margin
-322.08%
↑ 34.93%
FY20Y/Y Change
Revenue
71.9M
↓ 2.12%
Net Income
-278.0M
↑ 17.58%
Net Profit Margin
-386.9%
↓ 64.82%
FY21Y/Y Change
Revenue
55.3M
↓ 23.03%
Net Income
-199.4M
↓ 28.27%
Net Profit Margin
-360.55%
↑ 26.35%
FY22Y/Y Change
Revenue
51.3M
↓ 7.17%
Net Income
-92.8M
↓ 53.45%
Net Profit Margin
-180.78%
↑ 179.77%
FY23Y/Y Change
Revenue
57.4M
↑ 11.84%
Net Income
-55.2M
↓ 40.54%
Net Profit Margin
-96.11%
↑ 84.67%
Q1 FY23Q/Q Change
Revenue
10.4M
↓ 28.89%
Net Income
-22.1M
↑ 54.92%
Net Profit Margin
-212.04%
↓ 114.71%
Q2 FY23Q/Q Change
Revenue
13.7M
↑ 31.99%
Net Income
-15.6M
↓ 29.17%
Net Profit Margin
-113.79%
↑ 98.25%
Q3 FY23Q/Q Change
Revenue
15.7M
↑ 14.14%
Net Income
-9.0M
↓ 42.79%
Net Profit Margin
-57.03%
↑ 56.76%
Q4 FY23Q/Q Change
Revenue
17.6M
↑ 11.93%
Net Income
-8.5M
↓ 4.91%
Net Profit Margin
-48.45%
↑ 8.58%
Q1 FY24Q/Q Change
Revenue
14.5M
↓ 17.43%
Net Income
-11.7M
↑ 37.05%
Net Profit Margin
-80.42%
↓ 31.97%
Q2 FY24Q/Q Change
Revenue
14.3M
↓ 1.7%
Net Income
-16.5M
↑ 41.71%
Net Profit Margin
-115.94%
↓ 35.52%
FY18Y/Y Change
Total Assets
560.2M
↑ 26.92%
Total Liabilities
611.8M
↑ 87.55%
FY19Y/Y Change
Total Assets
408.8M
↓ 27.03%
Total Liabilities
632.7M
↑ 3.41%
FY20Y/Y Change
Total Assets
469.1M
↑ 14.73%
Total Liabilities
772.8M
↑ 22.15%
FY21Y/Y Change
Total Assets
374.8M
↓ 20.09%
Total Liabilities
713.4M
↓ 7.69%
FY22Y/Y Change
Total Assets
607.4M
↑ 62.05%
Total Liabilities
165.6M
↓ 76.79%
FY23Y/Y Change
Total Assets
382.0M
↓ 37.11%
Total Liabilities
169.0M
↑ 2.06%
Q1 FY23Q/Q Change
Total Assets
538.6M
↓ 11.34%
Total Liabilities
168.0M
↑ 1.44%
Q2 FY23Q/Q Change
Total Assets
446.6M
↓ 17.07%
Total Liabilities
166.5M
↓ 0.91%
Q3 FY23Q/Q Change
Total Assets
413.6M
↓ 7.4%
Total Liabilities
167.5M
↑ 0.6%
Q4 FY23Q/Q Change
Total Assets
382.0M
↓ 7.64%
Total Liabilities
169.0M
↑ 0.92%
Q1 FY24Q/Q Change
Total Assets
371.3M
↓ 2.8%
Total Liabilities
166.4M
↓ 1.52%
Q2 FY24Q/Q Change
Total Assets
362.0M
↓ 2.5%
Total Liabilities
168.3M
↑ 1.14%
FY18Y/Y Change
Operating Cash Flow
-112.9M
↓ 43.86%
Investing Cash Flow
176.7M
↓ 413.68%
Financing Cash Flow
225.2M
↑ 13499.03%
FY19Y/Y Change
Operating Cash Flow
-238.2M
↑ 111.04%
Investing Cash Flow
-83.1M
↓ 147.0%
Financing Cash Flow
1.3M
↓ 99.43%
FY20Y/Y Change
Operating Cash Flow
-250.4M
↑ 5.12%
Investing Cash Flow
10.7M
↓ 112.91%
Financing Cash Flow
263.1M
↑ 20278.39%
FY21Y/Y Change
Operating Cash Flow
-207.9M
↓ 16.99%
Investing Cash Flow
124.5M
↑ 1061.22%
Financing Cash Flow
91.9M
↓ 65.08%
FY22Y/Y Change
Operating Cash Flow
-187.0M
↓ 10.04%
Investing Cash Flow
1.2B
↑ 826.96%
Financing Cash Flow
-758.8M
↓ 926.05%
Q1 FY23Q/Q Change
Operating Cash Flow
-11.2M
↓ 90.95%
Investing Cash Flow
-43.0M
↓ 209.92%
Financing Cash Flow
-56.2M
↑ 58.55%
Q2 FY23Q/Q Change
Operating Cash Flow
-12.4M
↑ 10.83%
Investing Cash Flow
11.0M
↓ 125.66%
Financing Cash Flow
-80.7M
↑ 43.46%

Technicals Summary

Sell

Neutral

Buy

Theravance Biopharma Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Theravance Biopharma Inc
Theravance Biopharma Inc
10.83%
-6.98%
-3.3%
12.82%
-48.9%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Theravance Biopharma Inc
Theravance Biopharma Inc
NA
NA
-0.05
-1.01
-0.19
-0.06
NA
3.96
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Theravance Biopharma Inc
Theravance Biopharma Inc
Buy
$421.7M
-48.9%
NA
-73.61%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on Theravance Biopharma Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 17.56M → 14.25M (in $), with an average decrease of 9.6% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, -8.51M → -16.52M (in $), with an average decrease of 39.4% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 85.8%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 32.0%

Institutional Holdings

  • Madison Avenue Partners, LP

    17.40%

  • Weiss Asset Management LP

    15.24%

  • Baupost Group LLC

    8.59%

  • BlackRock Inc

    7.73%

  • Irenic Capital Management LP

    5.64%

  • Newtyn Management LLC

    4.34%

Company Information

theravance biopharma is a biopharmaceutical company with one approved product, vibativ® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.

Organization
Theravance Biopharma Inc
Employees
99
CEO
Mr. Rick E. Winningham M.B.A.
Industry
Health Technology

Discover More

FAQs